Trial Profile
Effects of iron deficiency and its treatment on fibroblast growth factor 23 (FGF23) in patients treated with chronic haemodialysis therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary) ; Iron sucrose
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms D-IDENTIFY
- 25 Jul 2014 New trial record